The KC26-Lipo system works by inhibiting lactate metabolism in breast cancer, repolarizing tumor-associated macrophages (TAMs), and suppressing tumor angiogenesis through the HIF-1α/VEGF pathway. The gene discussed is VEGFA; the disease is neoplasm.